Drug Discovery · Biotechnology
Relay Therapeutics revenue, results and funding
Relay Therapeutics filed revenue of $15.4M for 2025.
Data updated Nov 22, 2026 · Back to the company report
$15.4MRevenue, 2025
−$276.5MNet income, 2025
Results by year
| Year | Revenue | Net income | Total assets | LANG_CR_S_M_TAX_EXPENSE | LANG_CR_S_M_CAPEX | LANG_CR_S_M_SBC | LANG_CR_S_M_RND | LANG_CR_S_M_OPERATING_INCOME | LANG_CR_S_M_CASH | LANG_CR_S_M_ACQUISITIONS |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $15.4M | −$276.5M | $621.3M | $0 | $410k | $62.4M | $261.4M | −$302.7M | $84M | – |
| 2024 | $10M | −$337.7M | $871.3M | $0 | $2M | $94.1M | $319.1M | −$372.5M | $124.3M | – |
| 2023 | $25.5M | −$342M | $844M | $0 | $4.1M | $86M | $330M | −$373M | $143.7M | – |
| 2022 | $1.4M | −$290.5M | $1.1B | $0 | $9.1M | $56.1M | $246.4M | −$299.3M | $151.8M | – |
| 2021 | $3M | −$363.9M | $1B | $0 | $3.5M | $48.5M | $172.7M | −$364.7M | $280.1M | $25.3M |
| 2020 | $82.7M | −$52.4M | $799.8M | $0 | $1.9M | $32M | $99.9M | −$55.8M | $447.6M | – |
| 2019 | – | −$75.3M | $393.1M | $0 | $8M | $4.5M | $70.3M | −$84M | $42M | – |
Sources: SEC
How to cite
Relay Therapeutics, Financials. Alion, Nov 22, 2026. https://alion.io/company/relaytx/financials
